The company's potential launch of a new device will likely be pushed back.
The company's lead product gained a big indication approval from the FDA.
Avita Medical Inc. (RCEL) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through...
Indaptus (INDP) announces positive pre-clinical efficacy data from a poster presentation made at a scientific conference from its proprietary Decoy platform pre-clinical study. Stock is up 22%.
Does Avita Medical Inc. (RCEL) have what it takes to be a top stock pick for momentum investors? Let's find out.
Novo Nordisk (NVO) increases annual guidance for the year 2023 on higher sales expectations for Ozempic and Wegovy.
Pharma Goliath Novo Nordisk (NVO) inks collaboration agreement with Aspect Biosystems to develop and commercialize transformative cell therapy treatments for type I diabetes patients.
Aurinia Pharmaceuticals (AUPH) announces the issue of its new and refined method-of-use patent, supplementing its existing patent, for Lupkynis to treat lupus nephritis. Shares are up 11%.
Avita Medical Inc. (RCEL) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
The FDA accepts Pacira's (PCRX) sNDA filing, which seeks to expand the label of its pain drug Exparel to include both sciatic and femoral nerve blocks. A final decision is expected by November 2023.